Home
Portfolio
Strategy
Team
News
Contact
Investor Login
Home
Portfolio
Strategy
Team
News
Contact
FDA GRANTS QIDP AND FAST TRACK DESIGNATIONS TO CIDARA THERAPEUTICS’ REZAFUNGIN PROPHYLAXIS DEVELOPMENT PROGRAM
Read Article
News
2018
2017
Archive
September 25, 2018
fda grants qidp and fast track designations to cidara therapeutics’ rezafungin prophylaxis development program
September 24, 2018
nodthera announces the appointment of adam keeney phd as president and chief executive officer
September 12, 2018
kinestral’s halio smart-tinting glass selected for integration into katerra smart homes & buildings
September 12, 2018
cidara therapeutics appoints david gollaher, ph.d., to board of directors
September 10, 2018
biodesy announces new ceo and $20 million series c financing to accelerate expansion into biotherapeutics discovery and development market
September 10, 2018
flexion therapeutics announces publication of phase 2 diabetes data in september issue of rheumatology
August 21, 2018
audentes announces regenerative medicine advanced therapy (rmat) designation granted by the fda to at132 for the treatment of x-linked myotubular myopathy
August 10, 2018
ovascience and millendo therapeutics announce merger to create leading rare endocrine disease company
August 9, 2018
viveve reports second quarter 2018 financial results and provides corporate update
August 9, 2018
cidara provides corporate update and reports second quarter 2018 financial results
August 7, 2018
akouos raises $50 million series a financing and expands team to advance precision genetic therapies that restore and preserve hearing
August 7, 2018
audentes therapeutics reports second quarter 2018 financial results and provides update on aspiro, the phase 1/2 clinical trial of at132 in patients with x-linked myotubular myopathy
August 7, 2018
nohla therapeutics receives fda fast track designation for dilanubicel for allogeneic cord blood transplant patients
July 31, 2018
promotions and team expansion!
August 1, 2018
crinetics pharmaceuticals announces pricing of initial public offering
July 31, 2018
nohla announces the hiring of dr. sarah noonberg as cmo and appointment of dr. colleen delaney as cso
July 16, 2018
nohla therapeutics receives fda orphan drug designation for dilanubicel for hematopoietic stem cell transplant patients
July 12, 2018
nohla therapeutics announces second closing of $56 million series b financing
July 10, 2018
rare endocrine disease biotech crinetics pharmaceuticals sets terms for $80 million ipo
June 26, 2018
nodthera secures £28 million ($40 million) series a financing
June 26, 2018
zemdri (plazomicin) approved by fda for the treatment of adults with complicated urinary tract infections (cuti)
June 23, 2018
impel neuropharma announces fda clearance of ind for pivotal phase 3 study of inp104 for acute treatment of migraine
June 21, 2018
crinetics pharmaceuticals awarded up to $3.2 million in sbir grants for congenital hyperinsulinism and acromegaly
June 15, 2018
nohla announces presentation of dilanubicel (nla101) data at eha annual meeting showcasing excellent long-term survival outcomes
June 8, 2018
phase 2 study shows promising results for potential mucus clearance drug
June 7, 2018
spyryx spx-101 phase 2 hope-1 trial shows improvement in lung function in patients with cystic fibrosis via novel modulation of enac
June 6, 2018
nohla receives ema prime designation for dilanubicel (nla101) to treat hematopoietic stem cell transplant patients
June 5, 2018
audentes announces priority medicines (prime) designation granted by the european medicines agency to at132 for the treatment of x-linked myotubular myopathy
May 31, 2018
scpharmaceuticals inc. provides regulatory update on furoscix®
May 30, 2018
nouscom appoints adrian woolfson, m.d., ph.d as chief medical officer
May 22, 2018
cidara therapeutics announces offering of common stock and warrants
May 21, 2018
cidara therapeutics and rutgers university awarded $5.5 million grant from nih
May 17, 2018
nohla announces eha abstract acceptance on dilanubicel (nla101) off-the-shelf cell therapy showing excellent long-term survival outcomes
May 15, 2018
nohla therapeutics announces closing of $45 million series b financing
May 10, 2018
5am and homology medicines receives award for revolutionary new therapeutic or platform startup from new england venture capital association
May 9, 2018
escient pharmaceuticals launches with $40 million series a financing
May 9, 2018
audentes therapeutics reports first quarter 2018 financial results and provides corporate update
April 25, 2018
mackay’s rallybio rare disease startup raises $37m in first funding round
April 19, 2018
pear therapeutics and sandoz announce deal to commercialize prescription digital therapeutics
April 17, 2018
ceterix® orthopaedics announces fda clearance of the novostitch® pro meniscal repair system
April 17, 2018
rarecyte introduces the cytefinder® ht instrument at aacr for high throughput slide-based imaging optimized for single cell liquid biopsy
April 16, 2018
aprea therapeutics presents results from phase ib/ii clinical study of apr-246 and azacitidine (aza) in patients with tp53 mutant myelodysplastic syndromes (mds)
April 4, 2018
arvinas completes $55 million series c financing to advance protein degradation platform
March 29, 2018
homology medicines announces pricing of initial public offering
March 22, 2018
nohla therapeutics selects advanced therapies business unit of wuxi apptec to manufacture universal donor cell therapies
March 21, 2018
cidara therapeutics provides clinical data updates for its lead antifungal rezafungin
March 20, 2018
following its blueprint: ideaya biosciences
March 19, 2018
take this app and call me in the morning – a look at pear therapeutics’ digital reset application
March 19, 2018
cidara therapeutics reports positive topline results from phase 2 strive trial of lead antifungal rezafungin
March 15, 2018
ideaya biosciences raises $94 million crossover series b financing
March 13, 2018
ideaya biosciences and cancer research uk announce partnership agreement to develop small molecule inhibitors of parg
March 13, 2018
ideaya biosciences appoints julie hambleton, m.d., as senior vice president and chief medical officer, head of development
March 13, 2018
crinetics pharmaceuticals completes $63.5 million series b financing
March 1, 2018
pear therapeutics to collaborate with novartis to develop prescription digital therapeutics
February 13, 2018
nohla therapeutics initiates global launch phase 2 trial of nla101 in patients with aml
February 12, 2018
audentes therapeutics announces dosing of first patient in valens, a phase 1/2 clinical trial of at342 for the treatment of crigler-najjar syndrome
February 7, 2018
impel neuropharma announces positive results of phase 1 clinical trial of inp104 for treatment of acute migraine headache
February 7, 2018
scientist.com adds accomplished pharma executive arne brandon to management team
February 7, 2018
audentes therapeutics announces selection of optimized clinical development candidate for pompe disease program
February 1, 2018
chrono therapeutics announces appointment of david happel as chief executive officer
February 1, 2018
ceterix announces completion of groundbreaking study of repair for meniscal tears previously thought unrepairable
January 29, 2018
audentes therapeutics announces the closing of its public offering and full exercise of the underwriters’ option to purchase additional shares
January 25, 2018
audentes therapeutics announces pricing of public offering of common stock
January 25, 2018
ventureforward blog series: diversity breeds diversity by 5am’s andy schwab
January 24, 2018
nohla therapeutics granted orphan drug designation in the european union for nla101 in the treatment of hematopoietic stem cell transplantation
January 23, 2018
audentes therapeutics announces proposed public offering of common stock
January 17, 2018
homology medicines appoints matthew r. patterson to board of directors
January 8, 2018
nohla therapeutics announces hiring of jim johnson as chief financial officer
January 4, 2018
neurogastrx, inc. raises $45m series a to bring lead gi candidate through proof of concept, jim o’mara named chief executive officer
January 4, 2018
arvinas announces research collaboration and license agreement with pfizer inc. for the discovery and development of protein degradation drug candidates
January 4, 2018
expansion therapeutics raises $55.3 million in series a financing to advance portfolio of novel rna targeted small molecule medicines to treat rare diseases
January 3, 2018
expansion therapeutics raises $55.3 million in series a financing to advance portfolio of novel rna targeted small molecule medicines to treat rare diseases
January 2, 2018
pear therapeutics completes $50 million series b financing
December 21, 2017
millendo therapeutics announces acquisition of alizÉ pharma sas to expand orphan endocrinology pipeline
December 18, 2017
5am ventures appoints amy burroughs as executive-in-residence
December 11, 2017
agc and kinestral technologies announce joint ventures to accelerate global adoption of halio™ smart-tinting glass
December 7, 2017
purigen biosystems appoints life science industry veteran barney saunders, phd as chief executive officer
November 30, 2017
akouos to build premier gene therapy company focused on hearing and balance disorders
November 29, 2017
scpharmaceuticals inc. announces closing of over-allotment option in its initial public offering
November 28, 2017
cidara therapeutics completes enrollment in phase 2 strive trial evaluating novel antifungal rezafungin (cd101 iv) in invasive fungal infections
November 21, 2017
biodesy delta system enables researchers to discover novel mechanism involved in infectious disease
November 21, 2017
arvinas and macroceutics establish del screening collaboration on undruggable targets
November 20, 2017
flexion therapeutics announces full commercial launch and nationwide availability of zilretta™
November 16, 2017
arvinas expands strategic license agreement with genentech
November 11, 2017
arvinas nominates oral clinical candidate for androgen receptor degrader program
November 8, 2017
millendo therapeutics announces positive topline phase 2 results of atr-101 in classic congenital adrenal hyperplasia
November 7, 2017
takeda and portal instruments announce collaboration to develop needle-free drug delivery device
November 6, 2017
nouscom raises €42 million series b financing
October 31, 2017
impel neuropharma announces first patient dosed in phase 1 clinical trial of inp104 for treatment of acute migraine headache
October 26, 2017
crinetics pharmaceuticals initiates phase 1 study of lead candidate crn00808 for acromegaly
October 24, 2017
scpharmaceuticals files for a $100 million ipo
October 18, 2017
spyryx biosciences announces first patient enrolled in phase 2 clinical trial of spx-101 for the treatment of cystic fibrosis
October 18, 2017
pear therapeutics receives expedited access pathway designation from fda for reset-o™ prescription digital therapeutic to treat opioid use disorder
October 18, 2017
viveve releases preliminary third quarter 2017 financial results
October 16, 2017
aprea therapeutics announces first patients enrolled in phase ib/ii clinical study of apr-246 for the treatment of esophageal cancer
October 6, 2017
flexion therapeutics announces fda approval of zilretta™ (triamcinolone acetonide extended-release injectable suspension) for osteoarthritis (oa) knee pain
October 3, 2017
impel neuropharma board announces appointment of jon congleton as ceo
September 29, 2017
nohla therapeutics awarded $6.9 million grant from cirm for the treatment of patients with acute myeloid leukemia
September 27, 2017
fda selects participants for new digital health software pre-certification pilot program; includes pear therapeutics
September 27, 2017
audentes therapeutics announces rare pediatric disease and fast track designations for at132 for the treatment of x-linked myotubular myopathy
September 21, 2017
audentes therapeutics announces dosing of first patient in aspiro, a phase 1/2 clinical trial of at132 for the treatment of x-linked myotubular myopathy
September 20, 2017
arvinas appoints dr. john houston as president and chief executive officer
September 15, 2017
pear therapeutics obtains fda clearance of the first prescription digital therapeutic to treat disease
September 7, 2017
crinetics pharmaceuticals awarded two sbir grants to develop new therapeutics for congenital hyperinsulinism and cushing’s disease
August 29, 2017
rarecyte completes $30m private financing for commercial expansion of rare cell detection technology for liquid biopsies
August 11, 2017
viveve announces second quarter 2017 financial results and strategic partnership with incontrol medical, llc
August 11, 2017
viveve announces second quarter 2017 financial results and strategic partnership with incontrol medical, llc
August 8, 2017
aprea therapeutics announces first patient enrolled in phase ib/ii clinical study of apr-246 for the treatment of platinum-resistant high-grade serous ovarian cancer
August 8, 2017
aprea therapeutics announces first patient enrolled in phase ib/ii clinical study of apr-246 for the treatment of platinum-resistant high-grade serous ovarian cancer
August 4, 2017
kinestral technologies receives the 2017 north american smart glass new product innovation award
August 1, 2017
homology medicines announces $83.5 million series b financing to advance lead development candidate and amendr™ in vivo gene editing technology
July 13, 2017
crinetics pharmaceuticals awarded $2.8 million sbir grant to support development of acromegaly drug candidate crn00808
July 12, 2017
portal instruments appoints wendy dwyer as chief business officer
June 27, 2017
viveve selected for inclusion in russell 2000(r) index
June 20, 2017
spyryx biosciences expands development award with cystic fibrosis foundation; presents phase 1 data for spx-101 at the european cystic fibrosis conference
June 12, 2017
needle-free injection – portal prime: a digitally controlled, cloud-integrated jet injection system
June 7, 2017
bird rock bio completes single ascending dose human clinical trial for namacizumab; generates safety, tolerability, and pharmacokinetics data; prepares to initiate study in non-alcoholic fatty liver disease patients
May 24, 2017
pierre fabre buys up igenica preclinical i-o meds
May 24, 2017
aprea therapeutics announces first patients enrolled in phase ib/ii clinical study of apr-246 for the treatment of myelodysplastic syndrome
May 16, 2017
scientist.com raised $24 million in equity financing co-led by leerink transformation partners and 5am ventures.
May 12, 2017
the american journal of respiratory and critical care medicine publishes study of spyryx biosciences’ spx-101, a novel enac-targeted therapeutic for cystic fibrosis that restores mucus transport
April 25, 2017
phaserx receives positive opinion for orphan drug designation for prx-otc from european medicines agency
April 20, 2017
audentes therapeutics announces pricing of public offering of common stock
April 20, 2017
first installation of the world’s most responsive smart-tinting glass unveiled in san francisco
April 12, 2017
millendo therapeutics appoints mary lynne hedley, ph.d. and carole nuechterlein, j.d. to board of directors
April 12, 2017
nohla therapeutics announces collaboration with university of california, davis to optimize manufacturing process and supply cell therapy product for clinical trials
April 5, 2017
spyryx biosciences presents data and corporate update at two recent conferences in support of clinical candidate for cystic fibrosis
April 4, 2017
carb-x injects up to $48 million to accelerate first powered by carb-x portfolio of drug discovery and development projects to tackle antibiotic resistance
April 4, 2017
homology medicines appoints brad smith as chief financial officer
April 3, 2017
audentes therapeutics announces fda clearance of investigational new drug application for at132 to treat x-linked myotubular myopathy
March 27, 2017
rennovia enters piloting stage of its key bio-based hdo platform
March 22, 2017
aprea therapeutics announces research collaboration with memorial sloan kettering cancer center
March 20, 2017
audentes therapeutics announces presentation of data from recensus, a medical chart review of patients with x-linked myotubular myopathy (xlmtm)
March 17, 2017
viveve announces pricing of public offering of shares of common stock
March 13, 2017
homology medicines and novartis enter collaboration to develop new treatments using homology’s proprietary gene editing technology
March 13, 2017
nouscom’s neoantigen-based vaccine synergizes with nktr-214 to cure established tumors in preclinical model
February 28, 2017
genepeeks announces additional partnerships with the donor solution and 3 sisters surrogacy
February 22, 2017
5am founding partner john diekman named as new chairman of the scripps research institute in la jolla
February 21, 2017
cidara therapeutics reports unfavorable results of phase 2 radiant trial of cd101 topical in vvc
February 20, 2017
bay area’s kinestral, view see clear future in smart windows
February 17, 2017
arvinas presents new preclinical data on oral androgen receptor protac at asco 2017 genitourinary cancers symposium
February 7, 2017
nohla therapeutics appoints kathleen fanning as president and chief executive officer
February 6, 2017
spyryx biosciences announces successful completion of phase 1 clinical trial for spx-101 and planned phase 2 initiation in cystic fibrosis during 2017
February 2, 2017
kinestral technologies raises $65 million in series c funding, prepares to launch halio™, the world’s most advanced smart-tinting glass
February 2, 2017
audentes therapeutics announces fda clearance of investigational new drug application for at342 to treat crigler-najjar syndrome
February 1, 2017
genepeeks appoints industry leader matt posard as president and chief commercial officer
January 24, 2017
genepeeks launches preconception test for combined risk of passing on more than 1,000 serious genetic diseases
January 23, 2017
homology medicines and ideaya biosciences featured on biospace.com’s top 20 life science startups to watch in 2017
January 18, 2017
bird rock bio receives approval to start first in human clinical trial for namacizumab, enters into agreement with ge healthcare
January 17, 2017
pulmatrix drug candidate receives “qualified infectious disease product” (qidp) designation from the fda
January 9, 2017
audentes therapeutics provides full year 2017 strategic outlook and financial guidance
January 5, 2017
arvinas appoints dr. john houston as president of research and development and chief scientific officer
January 5, 2017
aprea therapeutics announces presentation at the 35th annual j.p. morgan healthcare conference in san francisco
December 12, 2016
flexion therapeutics submits new drug application for zilretta™ to treat knee osteoarthritis pain
December 12, 2016
achaogen announces positive results in phase 3 cuti and cre clinical trials of plazomicin
December 12, 2016
arvinas presents data on oral estrogen receptor protac degrader at 2016 san antonio breast cancer symposium
December 9, 2016
arvinas collaborators present data on bet protac degraders at 2016 ash annual meeting
December 5, 2016
nohla therapeutics announces closing of $43.5m series a financing to transform stem cell transplantation with innovative off the shelf, universal donor cellular therapy
November 29, 2016
arvinas presents data on its bet protac degraders at 2016 eortc-nci-aacr symposium
November 29, 2016
audentes therapeutics announces initiation of large-scale cgmp production at its gene therapy manufacturing facility
November 28, 2016
phaserx receives orphan drug designation from fda for prx-otc for the treatment of ornithine transcarbamylase deficiency
November 10, 2016
cidara provides corporate update and reports third quarter 2016 financial results
November 10, 2016
viveve announces new brand identity geneveve™ by viveve
November 10, 2016
viveve® reports record third quarter financial results
November 10, 2016
audentes therapeutics reports third quarter 2016 financial results and provides corporate update
November 8, 2016
phaserx announces positive safety results from large animal study with hybrid mrna delivery technology
November 7, 2016
phaserx reports third quarter 2016 financial results and provides corporate update
November 7, 2016
achaogen reports third quarter 2016 financial results and announces acceleration of expected timeline for reporting top-line results from plazomicin program
November 4, 2016
pulmatrix reports third quarter 2016 financial results and business update
November 2, 2016
cidara therapeutics and square 1 bank announce $20 million credit facility
October 20, 2016
5am ventures announces team additions
October 13, 2016
viveve® announces regulatory approval for viveve system in u.a.e. and lebanon
October 13, 2016
cidara therapeutics announces closing of public offering of common stock, including exercise of underwriter’s option to purchase additional shares
October 10, 2016
aprea therapeutics announces efficacy and safety data in high-grade serous ovarian cancer patients treated with apr-246 in presentation at 2016 european society for medical oncology (esmo) annual meeting
October 10, 2016
aprea therapeutics announces first patients enrolled in phase ii clinical study of apr-246 for the treatment of high-grade serous ovarian cancer
October 6, 2016
viveve® announces fda 510(k) clearance for the viveve system in the u.s.
September 21, 2016
cidara therapeutics selects first development candidate from its cloudbreak™ immunotherapy discovery platform
September 19, 2016
fiercebiotech names ideaya biosciences as one of its “fierce 15” biotech companies of 2016
September 19, 2016
scpharmaceuticals announces presentations on subcutaneous furosemide at hfsa annual meeting
September 15, 2016
homology medicines acquires license to novel aav technology to develop treatments for central nervous system disorders
September 8, 2016
chrono therapeutics raises $47.6 million in series b financing to advance its clinical platform for personalized drug therapy
September 1, 2016
achaogen completes patient enrollment in phase 3 epic clinical trial of plazomicin
August 31, 2016
audentes therapeutics reports second quarter 2016 financial results and provides corporate update
August 18, 2016
spyryx biosciences expands executive team, appoints pulmonary industry leader, alistair wheeler, md, mfpm as chief medical officer
August 17, 2016
audentes therapeutics announces first patient enrolled in the inceptus clinical assessment study of xlmtm
August 11, 2016
cidara reports second quarter 2016 financial results and provides corporate update
August 9, 2016
cidara therapeutics announces presentations addressing vulvovaginal candidiasis at upcoming idsog annual meeting
August 8, 2016
cleave biosciences raises $37 million series b financing
July 27, 2016
millendo therapeutics announces publication of positive phase 2a data for mle4901 for the treatment of polycystic ovary syndrome
July 21, 2016
galenica and relypsa announce agreement for galenica to acquire relypsa
July 19, 2016
audentes therapeutics announces pricing of initial public offering
July 12, 2016
supernus pharmaceuticals founder and ceo jack khattar joins scpharmaceuticals board of directors
June 14, 2016
viveve® announces pricing of $13.5 million public offering of shares of common stock and nasdaq uplisting
June 9, 2016
cidara doses first patient in phase 2 trial of cd101 topical to treat vulvovaginal candidiasis
June 6, 2016
aprea ab announces efficacy and safety data in high-grade serous ovarian cancer patients treated with investigational apr-246 presented at 2016 asco annual meeting
June 2, 2016
achaogen awarded $20 million contract option by barda to support development of plazomicin for multi-drug resistant gram-negative infections
May 31, 2016
fda grants qidp and fast track designation to cd101 topical, cidara therapeutics’ novel antifungal product candidate
May 31, 2016
5am ventures raises $285 million life science venture capital fund
May 17, 2016
purigen biosystems receives $18.2m in series a financing led by 5am ventures and roche venture fund
May 10, 2016
stora enso strengthens bio-based chemicals development and signs a joint technology development and license agreement with rennovia
May 9, 2016
epirus announces reprioritization of pipeline to solely focus on biosimilars to treat rare diseases and key leadership changes
May 3, 2016
ideaya biosciences raises $46 million series a and recruits leadership and advisory board
May 2, 2016
homology medicines emerges with next generation gene editing technology driven by industry-leading team in rare diseases
April 21, 2016
viveve® announces positive topline results for viveve i clinical trial
April 4, 2016
flexion therapeutics announces presentation of results from pivotal phase 2b and phase 3 clinical trials for zilretta™ at osteoarthritis research society international (oarsi) 2016 world congress
March 9, 2016
cancer company aprea closes eur 46 million (~usd 51 million) series b financing
February 3, 2016
pear therapeutics closes $20 million financing
February 3, 2016
venturewire: pear therapeutics raises $20m for digital substance-abuse treatment
January 11, 2016
achaogen announces enrollment of first patient in epic, a phase 3 clinical trial for the treatment of complicated urinary tract infections (cuti) with plazomicin
January 5, 2016
millendo licenses phase 2 polycystic ovary syndrome (pcos) drug candidate from astrazeneca and secures series b financing of $62 million to advance pipeline of endocrine disorder therapies
December 17, 2015
5am ventures announces promotions and team expansion
December 4, 2015
johnson & johnson announces completion of novira therapeutics, inc. acquisition
November 4, 2015
novira therapeutics announces acquisition agreement with johnson & johnson
November 4, 2015
scpharmaceuticals announces positive results from pivotal trial of its novel subcutaneous furosemide formulation in patients with heart failure
November 2, 2015
crinetics pharmaceuticals completes $40 million series a financing
October 25, 2015
portal instruments closes a $25 million series b financing to commercialize its transformative needle-free drug delivery system
October 13, 2015
fiercebiotech: audentes therapeutics may be eyeing ipo after a $65m crossover fund
October 6, 2015
the medicines company and symbio pharmaceuticals establish strategic partnership for ionsys® (fentanyl iontophoretic transdermal system) in japan
October 1, 2015
arvinas inks strategic license agreement with genentech
September 29, 2015
precision nanosystems raises $13.4m in series a financing
September 25, 2015
bellerophon therapeutics announces positive data from interim analysis of phase 2 long-term extension study of inopulse(r) for treatment of pulmonary arterial hypertension
September 25, 2015
the medicines company receives chmp positive opinion for ionsys® to treat post-operative pain in adult patients
August 27, 2015
novo nordisk to acquire calibrium llc and mb2 llc
August 26, 2015
bd to acquire cellular research to develop a leading genomics platform for single cell analysis
August 11, 2015
5am ventures appoints yujiro hata as executive-in residence
August 3, 2015
cidara therapeutics initiates phase 1 study of lead antifungal product candidate cd101 iv
June 12, 2015
ruthigen and pulmatrix stockholders approve merger
June 4, 2015
arvinas publishes first peer-reviewed paper on its proprietary protac technology
May 25, 2015
chinese consortium enters into agreement to acquire ambrx
May 11, 2015
audentes therapeutics announces new data to be presented at american society of gene and cell therapy annual meeting
May 11, 2015
fda grants qidp and fast track designations to cd101 iv, cidara therapeutics’ lead antifungal product candidate
May 7, 2015
spyryx biosciences secures $18 million in series a financing
April 30, 2015
the medicines company announces fda approval of ionsys® (fentanyl iontophoretic transdermal system) for the management of acute post-operative pain for adult patients in the hospital
April 21, 2015
scpharmaceuticals announces start of pivotal trial for novel furosemide solution for subcutaneous delivery
April 16, 2015
mallinckrodt completes acquisition of ikaria
April 15, 2015
cidara therapeutics announces pricing of initial public offering
April 14, 2015
scpharmaceuticals elects dorothy coleman to board of directors and appoints brian piekos as chief financial officer
April 7, 2015
arvinas announces strategic r&d collaboration with merck to study novel protein degradation technology
April 7, 2015
viveve completes enrollment in the viveve i clinical trial
March 17, 2015
xconomy: in mental health therapy, cautious steps toward the pharmacodigital
March 16, 2015
ruthigen and pulmatrix enter into merger agreement
March 10, 2015
pear therapeutics closes financing
March 6, 2015
ceterix announces publication of studies demonstrating advantages of meniscus repair with minimally invasive orthopaedic suturing device
March 5, 2015
mallinckrodt pharmaceuticals to expand hospital growth platform with ikaria, inc. acquisition
February 25, 2015
relypsa announces pricing of public offering of common stock
February 13, 2015
bellerophon therapeutics announces pricing of its initial public offering
February 11, 2015
cidara therapeutics completes $42 million private series b financing
February 9, 2015
viveve appoints james atkinson chief business officer/president
February 5, 2015
cellular research unveils massively parallel single-cell sequencing technology; announces partnership program for drug discovery and diagnostics
February 2, 2015
flexion therapeutics initiates phase 3 clinical trial of fx006 in patients with osteoarthritis of the knee
January 28, 2015
wired article: this wearable helps you quit smoking by dosing you with nicotine
January 8, 2015
achaogen announces plazomicin granted qidp designation by fda
December 17, 2014
flexion therapeutics announces exercise of underwriters’ over-allotment option and closing of public offering of common stock
December 17, 2014
relypsa to be added to nasdaq biotechnology index
December 16, 2014
relypsa announces stephen d. harrison, m.a., ph.d., joins as senior vice president and chief scientific officer
December 15, 2014
relypsa announces fda acceptance of new drug application for patiromer for oral suspension to treat hyperkalemia
December 2, 2014
epirus biopharmaceuticals remicade® biosimilar, infimab™, launches in india
December 2, 2014
audentes therapeutics raises $42.5 million in series b financing
November 17, 2014
data from epirus’ phase 3 study of bow015, a biosimilar infliximab, to be presented as a late breaking poster at the american college of rheumatology annual meeting
November 17, 2014
relypsa announces key data presented presented at asn on long-term chronic treatment and early onset of action with patiromer for oral suspension
November 11, 2014
5am ventures announces venture partner and cfo appointments
November 10, 2014
novira therapeutics announces presentation of phase 1a safety and pharmacokinetic data for nvr 3-778
October 22, 2014
relypsa submits new drug application to u.s. fda seeking approval for patiromer for oral suspension to treat hyperkalemia
September 25, 2014
epirus and livzon mabpharm, inc. enter collaboration agreement for china
September 23, 2014
epirus announces positive 58 week follow up data for bow015 for treatment of rheumatoid arthritis
September 17, 2014
achaogen announces first patient enrollment in a phase 3 clinical trial of plazomicin to treat infections caused by carbapenem-resistant enterobacteriaceae (cre)
September 9, 2014
flexion therapeutics announces issuance of u.s. composition of matter patent for lead candidate fx006
September 4, 2014
novira therapeutics announces successful completion of phase 1a clinical study on nvr-1221 and commencement of phase 1b clinical studies
September 3, 2014
flexion therapeutics to start fx006 phase 3 pivotal trial in 2014; following fda meeting, development plan advanced by one year
August 7, 2014
flexion therapeutics reports second-quarter 2014 financial results
July 28, 2014
vbi and paulson capital announce completion of merger
July 1, 2014
bellerophon therapeutics names jonathan peacock chairman and chief executive officer
June 19, 2014
relypsa adds industry veterans daniel k. spiegelman and kenneth j. hillan to its board of directors
June 17, 2014
flexion therapeutics announces positive topline results from phase 2a pharmacokinetic trial with lead compound fx006
June 12, 2014
chrono therapeutics, inventor of wearable “smart” smoking cessation technology, secures $32 million in series a financing
June 11, 2014
phase 3 data demonstrate comparability of epirus’ bow015 to remicade® for treatment of rheumatoid arthritis
May 19, 2014
audentes therapeutics announces six abstracts to be presented at the american society of gene and cell therapy meeting may 21-24, 2014
May 9, 2014
paulson capital and variation biotechnologies enter into merger agreement
May 1, 2014
ceterix announces results from biomechanical studies of minimally invasive orthopaedic suturing device
April 30, 2014
flexion therapeutics initiates a phase 2b confirmatory dose-ranging trial with lead compound fx006
April 16, 2014
epirus closes $36 million series b financing
March 27, 2014
fiercebiotech: ruiyi banks $15m from a-list backers to amp up chinese r&d
March 20, 2014
johnson matthey davy technologies ltd. and rennovia, inc. to develop and commercialize production technology for bio-based glucaric acid and adipic acid
March 17, 2014
achaogen announces closing of initial public offering and exercise of underwriters’ over-allotment option to purchase additional shares
March 13, 2014
nature biotechnology’s academic spinouts of 2013
March 13, 2014
novira names christian s. schade chief executive officer
March 12, 2014
achaogen announces pricing of initial public offering
February 20, 2014
achaogen announces key appointments to leadership team and board
February 12, 2014
adm invests $25m in rennovia: the complete story
February 11, 2014
flexion therapeutics announces pricing of initial public offering
January 29, 2014
fluidigm and dvs sciences announce agreement for fluidigm to acquire dvs sciences – creating a single-cell technology powerhouse
January 9, 2014
epirus and ranbaxy announce signing of bow015 licensing partnership for broad range of territories
January 9, 2014
5am ventures announces senior leadership appointments
December 12, 2013
the medicines company agrees to acquire incline therapeutics, inc.
December 3, 2013
5am ventures raises $250 million life science venture capital fund
October 22, 2013
epirus and orygen biotecnologia announce signing of multiproduct biosimilar development, manufacturing and commercialization collaboration for brazil
October 17, 2013
biodesy inc. completes $15.0 million series a financing and appoints greg yap as chief executive officer
August 23, 2013
achaogen announces agreement with fda on a special protocol assessment for a phase 3 clinical trial of plazomicin to treat infections caused by carbapenem-resistant enterobacteriaceae (cre)
August 20, 2013
ambrx appoints peter kiener, ph.d., as chief scientific officer
July 30, 2013
regenx biosciences and audentes therapeutics enter into exclusive license agreement for development of treatments for serious, rare muscle diseases using nav™ vectors
July 16, 2013
ceterix announces u.s. launch of novel device for minimally invasive orthopaedic procedures
June 26, 2013
flexion’s fx006 demonstrates superior pain relief compared to standard-of-care in phase 2b osteoarthritis trial
June 14, 2013
ambrx and zhejiang medicine co., ltd. form collaboration to develop and commercialize ambrx’s antibody drug conjugate for breast cancer
May 30, 2013
pearl therapeutics named winner of 2013 tie50 “top startup” at tiecon 2013
May 15, 2013
relypsa announces appointment of john orwin as chief executive officer
May 4, 2013
dvs sciences introduces the cytof® 2 mass cytometer and new maxpar® panel kits for transformational high-parameter single cell analysis
May 3, 2013
ambrx initiates collaboration with bristol-myers squibb for discovery, development of next-generation antibody drug conjugates
May 3, 2013
bms partners again with ambrx, in up-to-$112m-and-up adc collaboration
April 24, 2013
achaogen awarded $60m contract option by barda for the clinical development of plazomicin
April 9, 2013
igenica appoints thi-sau migone, ph.d., as chief scientific officer
April 9, 2013
cleave biosciences adds new investor and $10 million to series a financing
April 4, 2013
astellas and ambrx initiate collaboration for discovery and development of next generation antibody drug conjugates for oncology
March 25, 2013
novira therapeutics completes $25 million series a financing
February 28, 2013
biotie: selincro (nalmefene) receives european marketing authorization
February 26, 2013
ucb to license worldwide rights to tozadenant in parkinson’s disease from biotie
January 22, 2013
ceterix orthopaedics completes $19.5 million series b financing
January 7, 2013
ambrx appoints lawson macartney, ph.d., dvm, chief executive officer
January 4, 2013
epirus biopharmaceuticals, inc. announces positive phase 1 data for bow-015
December 17, 2012
flexion’s fx006 achieves prolonged therapeutic concentrations in joints of osteoarthritis patients
December 14, 2012
biotie: selincro(tm) (nalmefene) receives positive opinion for approval in the european union
December 11, 2012
biotie’s tozadenant (syn115) meets primary and multiple secondary endpoints in phase 2b study in parkinson’s disease
December 4, 2012
flexion therapeutics secures $20 million in series b financing
November 13, 2012
pearl therapeutics raises $65 million series d to start pt003 phase 3
November 4, 2012
takeda to acquire envoy therapeutics, inc.
October 11, 2012
c. robert kidder joins board of directors of wildcat discovery technologies, inc.
October 4, 2012
anaphore announces name change to ruiyi and new additions to shanghai management team
October 4, 2012
ruiyi (formerly anaphore) and argen-x announce exclusive worldwide license agreement for argx-109, a novel anti-il-6 antibody
September 26, 2012
wildcat discovery technologies enters joint development agreement with japan’s asahi kasei corp. for rechargeable battery technology
September 18, 2012
igenica appoints mary haak-frendscho, ph.d., as chief executive officer
September 14, 2012
cystic fibrosis foundation therapeutics and pulmatrix initiate collaboration to accelerate pur118 in the treatment of cystic fibrosis
September 13, 2012
pearl therapeutics completes phase 2b study of glycopyrrolate, defines dose-response curve and identifies optimal dose of pt001
September 7, 2012
biotie has completed a directed share issue of eur 20 million to institutional and strategic investors
August 27, 2012
genomeweb/proteomonitor article: nolan lab profiles small-molecule inhibitors using new multiplexing method for dvs sciences’ cytof
August 24, 2012
novira therapeutics secures $23 million series a financing to advance development of antivirals for treatment of chronic hepatitis b and hiv infections
August 15, 2012
relypsa announces $80 million private financing transaction
August 3, 2012
atterocor launches innovative company focused on accelerated development of treatment for adrenal cancer; secures $16 million series a financing
July 7, 2012
lundbeck has made eur 10 million equity investment in biotie and the parties amend the selincro licensing agreement regarding territories outside the eu and us
July 5, 2012
biotie completes enrollment in phase 2b trial of tozadenant in parkinson’s disease
June 25, 2012
teleflex acquires innovative technology to reduce biological formation on medical devices
June 18, 2012
ambrx collaborates with merck to design and develop biologic drug conjugates
June 18, 2012
patricia scheller named ceo of viveve, inc.
June 12, 2012
igenica closes $33 million in series c funding
May 30, 2012
flexion’s lead osteoarthritis drug candidate demonstrates significant, prolonged improvement in pain and function in phase 2 trial
May 28, 2012
the viveve system receives health canada medical device license to non-surgically treat vaginal laxity following childbirth
May 21, 2012
pearl therapeutics receives tie50 award from global entrepreneurship network
May 15, 2012
wildcat discovery technologies article in may/june 2012 technology review
May 15, 2012
achaogen announces all objectives met in phase 2 plazomicin complicated urinary tract infections study and start of first-in-human study with achn-975
May 7, 2012
michael j. fox foundation expands funding to envoy
April 27, 2012
wildcat discovery technologies named one of technology review’s 2012 top 50 most innovative companies
March 22, 2012
anaphore announces acquisition of ruiyi in shanghai china for gpcr biologics drug discovery platform
March 13, 2012
flexion article: could this be orthopedics’ future?, orthopedics this week, 8 (9)
March 5, 2012
data presented at the 2012 european congress of psychiatry showing that selincro(tm) reduces total alcohol consumption by two-thirds on average after six months of treatment
March 1, 2012
biotie successfully completes imaging study with syn120
December 14, 2011
clinical neuroscientist, william z. potter, m.d., ph.d., joins envoy’s advisory board
December 7, 2011
pearl therapeutics reports positive phase 2b results of pt001 in patients with copd
December 5, 2011
dvs sciences appoints joseph victor as president and ceo
October 11, 2011
cleave biosciences raises $42 million in series a financing for novel cancer therapies
September 28, 2011
achaogen appoints chief medical officer kenneth hillan to chief executive officer
September 22, 2011
bristol-myers squibb and ambrx announce collaboration for novel biologics programs in diabetes and heart failure
September 6, 2011
fiercebiotech names pearl therapeutics a 2011 fierce 15 biotech
August 31, 2011
envoy garners florida governor’s 2011 business diversification award
August 30, 2011
pearl therapeutics announces positive results for phase 2b dose-ranging study of formoterol mdi
August 15, 2011
pulmatrix secures a $14 million financing to advance clinical programs in copd and cystic fibrosis
August 5, 2011
biotie therapies corp. interim report 1 january – 30 june 2011
July 25, 2011
biotie advances clinical program for syn120 with imaging study at johns hopkins center of excellence
July 14, 2011
dvs sciences raises $14.6 million in series a financing to advance commercialization of novel single-cell analysis technology
July 11, 2011
viveve sponsors study in japan for new procedure to treat vaginal laxity
June 20, 2011
anaphore appoints paul a. grayson president and ceo
June 16, 2011
pearl therapeutics advances its long-acting bronchodilator combination product candidate into four additional phase 2 studies
May 18, 2011
pearl therapeutics’ phase 2b results show a 50% improvement in lung function with pt003 compared to spiriva® and foradil® in patients with copd
April 29, 2011
pearl therapeutics to present complete pt003 results from phase 2b copd study in a late-breaker session at the american thoracic society annual meeting
April 7, 2011
biotie announces start of phase 2b trial of syn115 in parkinson’s disease
March 24, 2011
vbi progressing with vaccines that don’t require refrigeration
March 14, 2011
wildcat discovery technologies discloses fundamental advances in rechargeable battery materials technology
February 2, 2011
the acquisition of synosia therapeutics holding ag completed
February 1, 2011
marcadia may fetch up to $537 million in sale
January 10, 2011
biotie and synosia to combine to create a leading cns development company
December 30, 2010
roche acquires marcadia biotech
December 13, 2010
anaphore enters r&d partnership with mitsubishi tanabe pharma to develop and commercialize novel protein pharmaceuticals for autoimmune disorders
December 13, 2010
semprus biosciences lands another $18m
December 1, 2010
ground breaking data on synosia’s investigational new parkinson’s drug published in the journal of neuroscience
December 1, 2010
pearl therapeutics’ pt003 combination therapy for copd demonstrates superior bronchodilation compared to spiriva® and foradil® in randomized phase 2b study
November 30, 2010
ikaria® begins enrollment of pivotal trial for lucassin®
November 8, 2010
anaphore article in nature biotechnology 28, 1143 (2010)
October 19, 2010
pearl therapeutics raises $69 million series c financing
October 12, 2010
ucb and synosia therapeutics sign strategic alliance in neurology
October 12, 2010
synosia therapeutics raises $30m in series c financing
October 8, 2010
takeda and envoy form schizophrenia research alliance
September 29, 2010
synosia presents data from clinical trial of syn-118 as a new treatment for parkinson’s disease
September 22, 2010
semprus biosciences awarded $500,000 national science foundation grant
September 9, 2010
achaogen to present new data on achn-490 at the 50th annual icaac meeting
August 30, 2010
achaogen awarded contract worth up to $64 million by barda for the development of achn-490
August 17, 2010
kalobios, seeking to apply antibodies beyond cancer, sets sight on killing deadly lung invader
August 12, 2010
viveve-sponsored research to be published in journal of sexual medicine
July 15, 2010
ikaria® names chief science officer
July 13, 2010
viveve-sponsored research accepted for presentation at two prestigious international conferences
July 8, 2010
ikaria® names new chief financial officer
June 28, 2010
marcadia and lilly sign development, license agreement for novel glucagon program in severe hypoglycemia
June 15, 2010
women’s health company viveve sponsors award winning abstract at acog
June 8, 2010
ikaria® appoints chief medical officer
June 5, 2010
semprus biosciences selected as one of the “50 companies to watch” in md+di june issue
June 1, 2010
ikaria® names new head of research & development
May 5, 2010
pearl therapeutics’ bronchodilator combination therapeutic for copd to be presented at the american thoracic society annual meeting
April 14, 2010
synosia therapeutics’ syn-115 improves motor and non-motor function in patients with mild-to-moderate parkinson’s disease
April 7, 2010
achaogen completes $56 million series c financing
March 30, 2010
ikaria® acquires new drug application for lucassin®
March 29, 2010
pearl therapeutics announces positive results from phase 1 trial of pt003, a bronchodilator combination therapeutic for chronic obstructive pulmonary disease, and initiation of phase 2b trial
February 17, 2010
marcadia initiates phase i clinical trial of glp-1/gip dual agonist mar701
February 1, 2010
synosia announces positive interim results for potential first-in-class treatment for parkinson’s disease
February 1, 2010
pearl therapeutics raises $15 million to advance pt003, lama/laba combination bronchodilator for copd, into phase 2b study
January 29, 2010
flexion therapeutics announces agreements with four major pharmaceutical companies
January 26, 2010
envoy enters diabetes and obesity collaboration with merck & co., inc.
January 4, 2010
pearl therapeutics announces positive results from phase 2a trial of formoterol inhalation aerosol in chronic obstructive pulmonary disease
December 7, 2009
5am ventures raises $200m for 3rd life science venture capital fund
November 16, 2009
emerging drug developer: flexion therapeutics – a ruthless pursuit of the bold experiment
November 9, 2009
women’s sexual health company changes name in preparation for market entry
October 16, 2009
flexion therapeutics raises $33 million in series a financing
October 14, 2009
new drug discovery company envoy therapeutics raises $8 million
September 14, 2009
wildcat discovery technologies selected by alwayson as a goinggreen top 100 winner
September 14, 2009
achaogen announces achn-490 clinical data at the 49th annual icaac meeting
August 25, 2009
achaogen appoints john c. doyle to the newly created position of chief operating officer
August 10, 2009
ikaria to in-license worldwide rights to investigational portfolio from fibrex medical
July 6, 2009
ikaria to in-license biolinerx’s bl-1040
June 12, 2009
fda accepts final section of nda filing for lucassin®
June 1, 2009
entremed presents results of enmd-2076 phase 1 study in advanced cancer patients
May 16, 2009
achaogen data show rapid rise in rates of resistance to current antibiotics; illustrate global need for new, well-tolerated agents to address varied mechanisms of resistance
May 13, 2009
synosia therapeutics begins phase i trial of a new generation treatment for cognitive impairment
May 1, 2009
pulmatrix announces ph 1b/2a clinical trial of novel icalm therapy for flu
March 10, 2009
synosia announces second agreement with roche
March 9, 2009
igenica appoints dr. mike rothe as ceo after closing series a financing
March 3, 2009
achaogen signs $26.6 million contract with niaid for development of new therapy to treat resistant strains of niaid category a and b priority pathogens
February 24, 2009
pearl therapeutics secures $8 million in debt financing
February 9, 2009
entremed presents initial clinical results for enmd-2076
February 9, 2009
biotechs befriend non-dilutive funds
February 3, 2009
achaogen initiates phase 1 trial of achn-490 for treatment of multi-drug resistant gram-negative bacterial infections
January 8, 2009
achaogen receives ₤4.1 million award from the wellcome trust to advance its neoglycosides portfolio
January 7, 2009
anaphore, inc. announces $25 million series a financing
